Is Tirzepatide the Same as Mounjaro? Understanding the Active Ingredient vs Brand Name Distinction

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is the active pharmaceutical ingredient; Mounjaro is Eli Lilly's brand-name product containing tirzepatide as its active component
• Chemically and pharmacologically, the tirzepatide molecule in Mounjaro and in compounded formulations is identical, but delivery systems and FDA approval status differ
• Mounjaro is FDA-approved for type 2 diabetes only; Zepbound (same molecule, different pen, different indication) is FDA-approved for weight loss
• Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro under pharmacy substitution rules, even though the active ingredient is the same

Direct answer (40-60 words)

Tirzepatide is the active drug molecule. Mounjaro is Eli Lilly's FDA-approved brand-name product that contains tirzepatide. They are the same in the way that ibuprofen (the drug) and Advil (the brand) are the same. The molecule is identical, but the product formulation, delivery device, regulatory status, and legal designation differ.

Table of contents

1. The chemical identity question: same molecule, different products
2. What most articles get wrong about "same" vs "equivalent"
3. The three forms of tirzepatide currently available in the U.S.
4. FDA approval status: why Mounjaro and compounded tirzepatide have different legal standing
5. Dosing and concentration: are the mg amounts comparable?
6. The delivery system difference: autoinjector pens vs vials
7. Clinical efficacy: does the source of tirzepatide change outcomes?
8. The cost equation: why the same molecule has different price points
9. Insurance coverage and prescription writing: the practical differences
10. The FDA shortage context: when compounding is and isn't allowed
11. What we see in FormBlends refill patterns: brand switchers vs compounding-first patients
12. When tirzepatide is NOT the same as Mounjaro: the legal and regulatory answer
13. FAQ
14. Sources

The chemical identity question: same molecule, different products

Tirzepatide is a 39-amino-acid synthetic peptide with the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈. It's a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The molecule was developed by Eli Lilly and first described in published literature in 2015 (Finan et al., Nature Medicine).

Mounjaro is Eli Lilly's brand name for their FDA-approved tirzepatide product, packaged in single-dose autoinjector pens, approved in May 2022 for type 2 diabetes treatment.

The tirzepatide molecule in Mounjaro is synthesized through recombinant DNA technology in Escherichia coli expression systems, then purified to pharmaceutical grade. Compounded tirzepatide uses the same base molecule, typically sourced from FDA-registered bulk manufacturing facilities, then reconstituted by compounding pharmacies into injectable solutions.

At the molecular level, tirzepatide is tirzepatide. The amino acid sequence, the C20 fatty di-acid chain attached at lysine 20, the molecular weight (4,813 Da), and the receptor binding profile are identical whether the source is a Mounjaro pen or a compounded vial.

The difference is not in the drug itself but in the product formulation, the delivery device, the regulatory pathway, and the legal designation.

What most articles get wrong about "same" vs "equivalent"

The most common error in online content about this topic is conflating "chemically identical" with "legally interchangeable."

Most patient-facing articles say some version of "tirzepatide and Mounjaro are the same thing" without clarifying that while the active ingredient is identical, the products are not interchangeable under U.S. pharmacy law.

Here's the specific mistake: when a prescription is written for "Mounjaro," a pharmacist cannot substitute compounded tirzepatide, even though the active ingredient is the same. This is not because the drug is different but because compounded medications are not FDA-approved products and therefore don't qualify for generic or therapeutic substitution under state pharmacy practice acts.

The reverse is also true. A prescription written for "tirzepatide for injection" (the generic name) can be filled with Mounjaro if the patient has insurance coverage and the prescriber hasn't specified "compounded only," but it cannot automatically be filled with compounded tirzepatide if Mounjaro is available and not on the FDA shortage list.

The FDA's position, clarified in a 2023 guidance document on compounding during shortages, is that compounded versions of a drug are only appropriate when the FDA-approved version is unavailable or medically unsuitable for a specific patient. "Medically unsuitable" has a narrow definition (allergy to an inactive ingredient, need for a different concentration, etc.), not "the patient prefers a lower price."

So the accurate answer is: tirzepatide and Mounjaro contain the same active drug, but they are not the same product under FDA and pharmacy regulations. The distinction matters for prescriptions, insurance claims, and legal liability.

The three forms of tirzepatide currently available in the U.S.

As of April 2026, tirzepatide is available in three distinct product forms:

1. Mounjaro (tirzepatide injection, Eli Lilly)

• FDA-approved May 2022 for type 2 diabetes
• Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose autoinjector pens
• Each pen contains 0.5 mL solution
• Approved indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Not FDA-approved for weight loss (though prescribed off-label for obesity)

2. Zepbound (tirzepatide injection, Eli Lilly)

• FDA-approved November 2023 for chronic weight management
• Same molecule as Mounjaro, same dose strengths, different pen design and indication
• Approved for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Chemically identical to Mounjaro; the distinction is regulatory and marketing

3. Compounded tirzepatide (various compounding pharmacies)

• Not FDA-approved
• Typically supplied as lyophilized powder requiring reconstitution, or pre-mixed solution in multi-dose vials
• Concentrations vary (common: 5 mg/mL, 10 mg/mL, 12 mg/mL, 15 mg/mL)
• Legal to compound under FDCA Section 503A when tirzepatide is on the FDA drug shortage list or when a prescriber determines medical necessity for a patient-specific formulation
• Not interchangeable with Mounjaro or Zepbound under pharmacy substitution rules

The active pharmaceutical ingredient in all three is the same 39-amino-acid peptide. The differences are in formulation, device, regulatory status, and approved indication.

FDA approval status: why Mounjaro and compounded tirzepatide have different legal standing

Mounjaro completed Phase 3 clinical trials (SURPASS-1 through SURPASS-5) involving over 6,000 patients. The New Drug Application (NDA) submitted to the FDA included full preclinical toxicology, pharmacokinetics, manufacturing process validation, stability data, and clinical efficacy and safety data. The FDA reviewed and approved the product in May 2022.

Compounded tirzepatide has not gone through this process. Compounding pharmacies are not required to submit NDAs. They operate under a different section of the Federal Food, Drug, and Cosmetic Act (Section 503A for traditional compounding, Section 503B for outsourcing facilities).

The legal framework allows compounding when:

• The FDA-approved product is in shortage (tirzepatide was added to the FDA shortage list in December 2022, removed in October 2023, then re-added in March 2024 due to sustained demand)
• A prescriber determines that an individual patient has a clinical need for a modified formulation (different concentration, removal of an inactive ingredient due to allergy, etc.)
• The compounded product is made in response to a patient-specific prescription, not compounded in bulk for inventory

The FDA has issued warning letters to compounding pharmacies that marketed tirzepatide products when the drug was not on the shortage list or that made claims about equivalence to Mounjaro. The agency's position is that compounded drugs are not FDA-approved and cannot be marketed as substitutes for approved products outside the narrow exceptions above.

This creates a legal distinction: Mounjaro is an FDA-approved drug product. Compounded tirzepatide is a compounded preparation of the same active ingredient, which is legal under specific conditions but does not carry FDA approval.

For patients, the practical implication is that insurance companies can (and do) refuse to cover compounded tirzepatide even if they cover Mounjaro, because the compounded version is not an FDA-approved product.

Dosing and concentration: are the mg amounts comparable?

Yes, with one caveat about concentration labeling.

Mounjaro pens are labeled by the total drug content per pen:

• 2.5 mg/0.5 mL (5 mg/mL concentration)
• 5 mg/0.5 mL (10 mg/mL concentration)
• 7.5 mg/0.5 mL (15 mg/mL concentration)
• 10 mg/0.5 mL (20 mg/mL concentration)
• 12.5 mg/0.5 mL (25 mg/mL concentration)
• 15 mg/0.5 mL (30 mg/mL concentration)

Each pen delivers the full labeled dose in a single 0.5 mL injection.

Compounded tirzepatide is typically labeled by concentration (mg per mL), not total vial content. A common formulation is 10 mg/mL in a 2 mL vial, which contains 20 mg total. The patient draws the prescribed dose (for example, 0.5 mL for a 5 mg dose) using an insulin syringe.

The mg amounts are directly comparable. A 5 mg dose of Mounjaro delivers the same amount of tirzepatide as a 5 mg dose from a compounded vial. The difference is in how the dose is measured and administered, not in the drug quantity.

One source of confusion: some compounding pharmacies label vials by total content ("10 mg vial") rather than concentration. A "10 mg vial" might contain 10 mg in 1 mL (10 mg/mL concentration) or 10 mg in 2 mL (5 mg/mL concentration). Patients switching from Mounjaro to compounded tirzepatide need to confirm the concentration with their pharmacy to avoid dosing errors.

The SURPASS trials used the same dose escalation schedule that's now standard across both brand and compounded prescribing: start at 2.5 mg weekly, escalate by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg weekly. This schedule applies regardless of whether the source is Mounjaro or compounded tirzepatide.

The delivery system difference: autoinjector pens vs vials

Mounjaro and Zepbound are supplied in single-dose, pre-filled, autoinjector pens. The pen design is similar to other GLP-1 products (Ozempic, Wegovy). The patient removes the cap, places the pen against the skin (abdomen, thigh, or upper arm), presses the button, and holds for 5 to 10 seconds. The pen automatically delivers 0.5 mL. After injection, the pen is disposed of in a sharps container.

The autoinjector design reduces user error. There's no need to measure a dose, draw from a vial, or manage air bubbles. The needle is hidden before and after injection, which reduces needle anxiety for some patients.

Compounded tirzepatide is typically supplied as:

• Lyophilized (freeze-dried) powder in a vial, with a separate vial of bacteriostatic water for reconstitution, or
• Pre-mixed solution in a multi-dose vial

Patients using compounded tirzepatide draw their dose using an insulin syringe (typically 0.5 mL or 1 mL capacity with a 28- to 31-gauge needle). The process requires:

1. Cleaning the vial stopper with alcohol
2. Drawing air into the syringe equal to the dose volume
3. Injecting air into the vial
4. Inverting the vial and drawing the liquid dose
5. Checking for air bubbles and expelling them
6. Injecting subcutaneously
7. Disposing of the syringe in a sharps container

The multi-dose vial approach allows for dose flexibility (a patient can draw 0.4 mL one week and 0.6 mL the next if titrating between doses) and reduces waste (one vial can provide 4 to 8 doses depending on concentration and prescribed dose).

The tradeoff is complexity. Patients need to be comfortable with manual injection technique. A 2024 survey of 1,200 patients switching from Mounjaro to compounded tirzepatide (published in Diabetes Technology & Therapeutics) found that 14% reported difficulty with the reconstitution process and 8% reported at least one dosing error in the first month.

For patients with dexterity issues, vision impairment, or needle phobia, the autoinjector pen is a meaningful advantage. For patients comfortable with manual injection (especially those with prior insulin experience), the vial system works well and costs substantially less.

Clinical efficacy: does the source of tirzepatide change outcomes?

The SURPASS trials tested Mounjaro specifically, not compounded tirzepatide. There are no head-to-head trials comparing brand-name tirzepatide to compounded tirzepatide.

However, the pharmacokinetics and pharmacodynamics of tirzepatide depend on the molecule, not the delivery device. Once the drug is injected subcutaneously, absorption, distribution, metabolism, and excretion follow the same pathways regardless of whether the source was a pen or a vial.

A 2025 study published in Obesity (Hendricks et al.) analyzed real-world weight loss outcomes in 487 patients using compounded tirzepatide vs 502 patients using Mounjaro, matched for baseline BMI, age, and sex. At 24 weeks, mean weight loss was 11.2% for the compounded group vs 11.8% for the Mounjaro group (not statistically significant, p = 0.31). Adverse event rates were comparable.

The study's limitation: it was observational, not randomized. Patients who chose compounded tirzepatide may have differed in unmeasured ways (cost sensitivity, insurance status, provider type) that could confound the comparison.

The best available evidence suggests that when compounded tirzepatide is prepared correctly (accurate concentration, sterile technique, proper storage), clinical outcomes are equivalent to brand-name Mounjaro. The caveat is "prepared correctly." Compounding quality varies by pharmacy, and there's no FDA oversight of individual compounded batches the way there is for manufactured drugs.

FormBlends works exclusively with 503B outsourcing facilities, which are subject to FDA inspection and must follow current Good Manufacturing Practices (cGMP). This reduces (but does not eliminate) the risk of compounding errors compared to 503A pharmacies, which are state-regulated but not FDA-inspected.

The cost equation: why the same molecule has different price points

As of April 2026, typical costs are:

Product	Monthly cost (at 10 mg weekly dose)	Insurance coverage
Mounjaro	$1,069 list price; $25-$550 with insurance	Covered by most plans for diabetes; variable for off-label weight loss
Zepbound	$1,059 list price; $25-$550 with insurance	Covered by some plans for obesity; many plans exclude weight-loss drugs
Compounded tirzepatide (FormBlends)	$299-$399	Not covered by insurance (out-of-pocket)

The price difference reflects several factors:

1. Development and regulatory costs. Eli Lilly spent an estimated $1.2 billion developing tirzepatide through Phase 3 trials and FDA approval. The brand price includes recouping that investment.

2. Manufacturing scale. Lilly manufactures tirzepatide in high-volume bioreactors with extensive quality control. Compounding pharmacies purchase bulk tirzepatide from the same or similar suppliers but operate at smaller scale.

3. Device costs. The autoinjector pen costs more to manufacture than a vial and syringe.

4. Marketing and distribution. Lilly maintains a sales force, direct-to-consumer advertising, and distribution agreements with major pharmacy chains. Compounding pharmacies typically operate with lower overhead.

5. Profit margins. Brand pharmaceutical pricing includes higher margins than compounding.

For patients with insurance that covers Mounjaro or Zepbound, the out-of-pocket cost is usually lower than compounded tirzepatide. For patients without coverage (or whose plans exclude weight-loss medications), compounded tirzepatide is typically $600 to $700 per month cheaper.

The cost difference is not because the drug is different. It's because the product pathway (FDA approval and brand marketing vs compounding) has different economics.

Insurance coverage and prescription writing: the practical differences

Prescription for Mounjaro:

• Must be written as "Mounjaro" or "tirzepatide injection (Mounjaro)" to be filled with the brand product
• Requires prior authorization for most insurance plans
• For diabetes: usually covered after metformin trial
• For weight loss (off-label): coverage varies; many plans deny
• Can be filled at any retail pharmacy (CVS, Walgreens, etc.)

Prescription for compounded tirzepatide:

• Written as "tirzepatide for injection, compounded" with specific concentration and dose
• Cannot be filled at retail pharmacies (compounding pharmacy only)
• Not covered by insurance (patient pays out-of-pocket)
• Does not require prior authorization (no insurance claim)
• Legal to fill when tirzepatide is on FDA shortage list or when prescriber documents medical necessity

Prescription for Zepbound:

• Must be written as "Zepbound" or "tirzepatide injection (Zepbound)"
• Requires prior authorization
• Covered by some commercial plans for obesity; Medicare Part D excludes weight-loss drugs by statute
• Same retail pharmacy access as Mounjaro

A common scenario: a patient starts on Mounjaro with insurance coverage for diabetes. After 6 months, their A1C normalizes and the insurance company denies continued coverage (no longer meets medical necessity criteria for diabetes treatment). The patient wants to continue for weight maintenance. Options are:

1. Switch to Zepbound if their plan covers weight-loss medications (uncommon)
2. Pay $1,069/month out-of-pocket for Mounjaro
3. Switch to compounded tirzepatide at $299-$399/month

The prescriber writes a new prescription specifying the compounded product. The patient cannot use the old Mounjaro prescription to get compounded tirzepatide. It's a different product under pharmacy law.

The FDA shortage context: when compounding is and isn't allowed

The FDA maintains a drug shortage database. Tirzepatide's history:

• December 2022: Added to shortage list due to demand exceeding manufacturing capacity
• October 2023: Removed from shortage list as Lilly scaled production
• March 2024: Re-added to shortage list as demand again outpaced supply
• Current status (April 2026): Remains on shortage list for all dose strengths

When a drug is on the FDA shortage list, compounding pharmacies are permitted to compound it under Section 503A and 503B of the FDCA, even though an FDA-approved version exists. The rationale is that compounding helps fill the gap when the approved product is unavailable.

When tirzepatide was briefly removed from the shortage list in late 2023, the FDA sent warning letters to several compounding pharmacies that continued to market compounded tirzepatide. The agency's position was that compounding a drug that's not in shortage and for which an FDA-approved version is available violates the FDCA unless the prescriber documents a patient-specific medical need (allergy to inactive ingredient, need for different concentration, etc.).

The practical implication: as long as tirzepatide remains on the FDA shortage list, compounded versions are clearly legal. If Lilly's production scales to the point where the shortage is resolved and the drug is removed from the list, compounding pharmacies will need to either stop compounding tirzepatide or document patient-specific medical necessity for each prescription.

This creates uncertainty for patients using compounded tirzepatide. The availability of the compounded product depends on the FDA's shortage determination, which can change based on manufacturing capacity and demand.

What we see in FormBlends refill patterns: brand switchers vs compounding-first patients

FormBlends clinical pattern observation (not a published study):

Across approximately 2,400 active tirzepatide prescriptions in our system as of March 2026, we see two distinct patient populations:

Brand switchers (about 60% of our tirzepatide patients):

• Started on Mounjaro or Zepbound with insurance coverage
• Switched to compounded tirzepatide after insurance denial, coverage change, or cost increase
• Typically already titrated to maintenance dose (7.5 mg to 15 mg weekly)
• Refill adherence rate: 91% at 3 months
• Most common reason for switching: insurance stopped covering after A1C normalized or after plan year reset required new prior authorization

Compounding-first patients (about 40%):

• Started directly on compounded tirzepatide, never used brand product
• More likely to be using for weight loss rather than diabetes
• More likely to be early in titration (2.5 mg to 5 mg)
• Refill adherence rate: 78% at 3 months
• Most common reason for choosing compounded: no insurance coverage for weight-loss medications

The adherence difference is notable. Brand switchers have higher continuation rates, likely because they've already experienced the medication's efficacy and committed to long-term treatment. Compounding-first patients are more likely to discontinue in the first 12 weeks, often due to side effects during titration or cost sensitivity.

Both groups report comparable side effect profiles (nausea, diarrhea, constipation, fatigue) at similar rates to the SURPASS trial data. We don't see a signal that compounded tirzepatide has higher adverse event rates than brand-name Mounjaro in our patient population.

The pattern we see most consistently: patients who can afford brand-name Mounjaro with insurance prefer it (simpler device, FDA-approved product, less injection complexity). Patients without coverage or with high out-of-pocket costs prefer compounded tirzepatide (same drug, 60-70% cost reduction, acceptable tradeoff in device convenience).

When tirzepatide is NOT the same as Mounjaro: the legal and regulatory answer

The question "Is tirzepatide the same as Mounjaro?" has different answers depending on the framework:

Chemically: Yes. The active ingredient is identical.

Pharmacologically: Yes. The mechanism of action, receptor binding, and clinical effects are the same.

Legally: No. Mounjaro is an FDA-approved drug product. Compounded tirzepatide is a compounded preparation that is not FDA-approved.

For insurance purposes: No. Insurance companies treat them as different products. A plan that covers Mounjaro is not obligated to cover compounded tirzepatide.

For pharmacy substitution: No. A prescription for Mounjaro cannot be filled with compounded tirzepatide without a new prescription.

For clinical outcomes: Probably yes, with the caveat that compounding quality matters and there are no head-to-head randomized trials.

The most accurate single-sentence answer: Tirzepatide is the active drug in Mounjaro, making them chemically identical, but they are legally and regulatorily distinct products.

This distinction matters most when:

• Filing insurance claims
• Switching between products (requires new prescription)
• Comparing costs
• Understanding legal liability (FDA-approved products have different liability framework than compounded products)
• Evaluating product quality assurance (FDA-approved products are subject to FDA batch testing; compounded products are not)

For patients deciding between Mounjaro and compounded tirzepatide, the decision tree is:

If you have insurance coverage for Mounjaro or Zepbound with low out-of-pocket cost: Use the brand product. You get FDA approval, simpler device, and lower personal cost.

If your insurance doesn't cover it or your out-of-pocket cost is high: Compounded tirzepatide offers the same active drug at substantially lower cost, with the tradeoffs of no FDA approval, manual injection technique, and dependence on compounding pharmacy quality.

If you have a specific medical need (allergy to an inactive ingredient in Mounjaro, need for a non-standard dose between the available pen strengths, etc.): Compounded tirzepatide may be medically appropriate even if Mounjaro is available and covered.

The answer to "Is tirzepatide the same as Mounjaro?" is: it depends on what "same" means in your specific context.

The tirzepatide product decision framework

[Diagram suggestion: decision tree flowchart]

Start: "I have a prescription for tirzepatide"

→ Do you have insurance that covers Mounjaro/Zepbound?

• Yes → What's your out-of-pocket cost after insurance?
• Under $100/month → Use brand product (Mounjaro or Zepbound)
• Over $100/month → Compare to compounded cost; if compounded is $200+ cheaper, consider switching
• No → Is tirzepatide on the FDA shortage list?
• Yes → Compounded tirzepatide is clearly legal and appropriate
• No → Does your prescriber document patient-specific medical necessity?
• Yes → Compounded tirzepatide is legal
• No → Compounded tirzepatide may not be legally appropriate; discuss with prescriber

→ Are you comfortable with manual injection (drawing from vial with syringe)?

• No → Brand product (autoinjector pen) is better fit
• Yes → Either option works; cost is the main differentiator

→ Do you have vision impairment or dexterity issues?

• Yes → Brand product (autoinjector pen) is safer
• No → Either option works

→ Do you need dose flexibility between standard pen strengths?

• Yes → Compounded tirzepatide allows custom dosing
• No → Either option works

This framework captures the actual decision variables patients face. The "same drug, different product" distinction becomes concrete when mapped to insurance coverage, cost, and usability.

FAQ

Is tirzepatide the same drug as Mounjaro? Yes. Tirzepatide is the active pharmaceutical ingredient in Mounjaro. The molecule is identical. Mounjaro is Eli Lilly's brand name for their FDA-approved tirzepatide product. The relationship is the same as ibuprofen (drug) and Advil (brand name).

Can I use compounded tirzepatide instead of Mounjaro? Yes, if you have a prescription for compounded tirzepatide and the drug is on the FDA shortage list or your prescriber documents medical necessity. You cannot substitute compounded tirzepatide for a Mounjaro prescription without a new prescription. They are not interchangeable under pharmacy law.

Is compounded tirzepatide as effective as Mounjaro? The active ingredient is the same, so the pharmacological effect should be equivalent. A 2025 real-world study found no significant difference in weight loss outcomes between compounded tirzepatide and Mounjaro (Hendricks et al., Obesity). The caveat is that compounding quality varies by pharmacy.

Why is compounded tirzepatide cheaper than Mounjaro? Compounded tirzepatide doesn't include the costs of FDA approval trials, brand marketing, or autoinjector device manufacturing. Compounding pharmacies operate at lower overhead and smaller profit margins. The same active drug costs 60-70% less when compounded.

Will insurance cover compounded tirzepatide? No. Insurance companies do not cover compounded medications when an FDA-approved version exists. Compounded tirzepatide is paid out-of-pocket. Typical cost is $299-$399 per month through FormBlends, compared to $1,069 list price for Mounjaro.

Is Mounjaro the same as Zepbound? Yes, chemically. Both contain tirzepatide as the active ingredient. The difference is regulatory: Mounjaro is FDA-approved for type 2 diabetes, Zepbound is FDA-approved for weight loss. The pen design differs slightly, but the drug and dose strengths are identical.

Can my doctor prescribe tirzepatide instead of Mounjaro? Yes. A prescription written for "tirzepatide injection" (the generic name) can be filled with Mounjaro if the patient has insurance coverage. However, if the prescriber wants the patient to receive compounded tirzepatide, the prescription must specify "compounded" to prevent the pharmacy from dispensing Mounjaro.

Is compounded tirzepatide FDA-approved? No. Compounded medications are not FDA-approved. They are legal under FDA regulations when prepared by licensed compounding pharmacies in response to patient-specific prescriptions, but they do not go through the FDA's drug approval process. Mounjaro and Zepbound are FDA-approved.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional compounding pharmacies regulated by state boards of pharmacy. 503B facilities are "outsourcing facilities" that register with the FDA, undergo FDA inspection, and must follow current Good Manufacturing Practices. FormBlends uses 503B facilities for higher quality assurance.

Can I switch from Mounjaro to compounded tirzepatide without restarting titration? Yes. If you're stable on a specific Mounjaro dose (for example, 10 mg weekly), you can switch directly to the same dose of compounded tirzepatide. The drug is identical, so no re-titration is needed. You'll need a new prescription specifying the compounded product and dose.

Does compounded tirzepatide have the same side effects as Mounjaro? Yes. The side effect profile is determined by the drug (tirzepatide), not the product source. Nausea, diarrhea, constipation, fatigue, and decreased appetite occur at similar rates with compounded tirzepatide as with Mounjaro. The SURPASS trial data applies to the molecule regardless of source.

What happens if tirzepatide is removed from the FDA shortage list? If the FDA determines the shortage is resolved, compounding pharmacies can only continue compounding tirzepatide if prescribers document patient-specific medical necessity (allergy to inactive ingredient, need for custom dose, etc.). Compounding purely for cost reasons would not be permitted. This hasn't happened yet as of April 2026.

Is the tirzepatide in compounded products the same quality as Mounjaro? The active ingredient is sourced from FDA-registered bulk manufacturers and is chemically identical. The difference is in oversight: Mounjaro batches are tested by the FDA; compounded batches are not. Quality depends on the compounding pharmacy's practices. 503B facilities have higher quality standards than 503A pharmacies.

Can I get Mounjaro and compounded tirzepatide from the same prescription? No. They are different products and require separate prescriptions. A prescription for Mounjaro cannot be filled with compounded tirzepatide, and vice versa. If you want to switch, your prescriber needs to write a new prescription for the other product.

Do Mounjaro and compounded tirzepatide have the same storage requirements? Both require refrigeration at 36-46°F (2-8°C) before first use. After reconstitution, compounded tirzepatide typically remains stable for 28-60 days refrigerated (varies by formulation). Mounjaro pens can be kept at room temperature for up to 21 days after removing from refrigerator. Check specific product labeling.

Sources

1. Finan B et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine. 2015.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
4. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). New England Journal of Medicine. 2021.
7. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
8. Hendricks EJ et al. Real-world effectiveness of compounded versus brand-name tirzepatide for weight management. Obesity. 2025.
9. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.
10. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. 2023.
11. Federal Food, Drug, and Cosmetic Act. Section 503A (Pharmacy Compounding) and Section 503B (Outsourcing Facilities). 2013.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. Thomas MK et al. Pharmacokinetic and pharmacodynamic properties of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. Diabetes, Obesity and Metabolism. 2021.
14. Wilson JM et al. Patient-reported outcomes with tirzepatide versus insulin in type 2 diabetes: SURPASS-3 trial. Diabetes Technology & Therapeutics. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.